Bhandaru M, Rotte A. Monoclonal antibodies for the treatment of Melanoma: Present and future strategies. Methods Mol Biol. 2019;1904:83–108.
Article
CAS
Google Scholar
Lemaire V, Shemesh CS, Rotte A. Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. J Exp Clin Cancer Res. 2021;40(1):311.
Article
CAS
Google Scholar
Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, et al. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Mol Ther. 2021;29(2):555–70.
Article
CAS
Google Scholar
Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood). 2015;240(8):1087–98.
Article
CAS
Google Scholar
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021;19(3):151–72.
Article
Google Scholar
Yu S, Li A, Liu Q, Li T, Yuan X, Han X, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.
Article
Google Scholar
Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev. 2014;257(1):14–38.
Article
Google Scholar
Rotte A, Heery C, Gliner B, Tice D, Hilbert D. BCMA targeting CAR T cells using a novel D-domain binder for multiple myeloma: clinical development update. Immuno-Oncology Insights. 2022;3:13–24.
Article
Google Scholar
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet. 2021;398(10297):314–24.
Article
CAS
Google Scholar
Madduri D, Berdeja J, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al, editors. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Relapsed/Refractory Multiple Myeloma. ASH 62nd Annual Meeting; 2020 December 5–8, 2020; Virtual meeting.
Zhao L, Cao YJ. Engineered T Cell Therapy for Cancer in the clinic. Frontiers in Immunology. 2019;10.
Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-effectiveness of chimeric Antigen receptor T-Cell therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2019;111(7):719–26.
Article
Google Scholar
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for Cytokine Release Syndrome after chimeric Antigen receptor T-cell therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016;6(6):664–79.
Article
CAS
Google Scholar
Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B. Dose response association for CAR-T cells. A systematic review of clinical studies. J Immunother Cancer. 2022. https://jitc.bmj.com/content/10/12/e005678.long.
Jin Z, Xiang R, Qing K, Li X, Zhang Y, Wang L, et al. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Ann Hematol. 2018;97(8):1327–35.
Article
CAS
Google Scholar
Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-hodgkin lymphoma. Signal Transduct Target Ther. 2020;5(1):134.
Article
CAS
Google Scholar
Wudhikarn K, Bansal R, Khurana A, Hathcock M, Ruff M, Carabenciov ID, et al. Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter? ASCO Annual Meeting: J Clin Oncol; 2021. p. e19556.
Google Scholar
Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19.
Article
CAS
Google Scholar
Sievers S, Watson G, Johncy S, Adkins S. Recognizing and grading CAR T-Cell toxicities: an Advanced Practitioner Perspective. Front Oncol. 2020;10:885.
Article
Google Scholar
Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric Antigen receptor T cell therapy: insights into mechanisms and Novel Therapies. Front Immunol. 2020;11:1973.
Article
CAS
Google Scholar
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020;396(10254):839–52.
Article
Google Scholar
Jiang H, Liu L, Guo T, Wu Y, Ai L, Deng J, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019;98(7):1721–32.
Article
CAS
Google Scholar
Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449–59.
Article
CAS
Google Scholar
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
Article
CAS
Google Scholar
Wang X, Zhao L, Wang J, Yao Y, Wang J, Ji S, et al. Correlation of Cytokine Release Syndrome with Prognosis after chimeric Antigen receptor T cell therapy: analysis of 54 patients with relapsed or refractory multiple myeloma. Front Immunol. 2022;13:814548.
Article
CAS
Google Scholar
Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.
Article
CAS
Google Scholar
Geyer MB, Riviere I, Senechal B, Wang X, Wang Y, Purdon TJ, et al. Autologous CD19-Targeted CAR T cells in patients with residual CLL following initial Purine Analog-Based therapy. Mol Ther. 2018;26(8):1896–905.
Article
CAS
Google Scholar
Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947–53.
Article
CAS
Google Scholar
Zhang Q, Hu H, Chen SY, Liu CJ, Hu FF, Yu J, et al. Transcriptome and Regulatory Network analyses of CD19-CAR-T immunotherapy for B-ALL. Genomics Proteom Bioinf. 2019;17(2):190–200.
Article
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Article
Google Scholar
Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. 2014;3:82.
Article
Google Scholar
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence–imprecision. J Clin Epidemiol. 2011;64(12):1283–93.
Article
Google Scholar
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence–indirectness. J Clin Epidemiol. 2011;64(12):1303–10.
Article
Google Scholar
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407–15.
Article
Google Scholar
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, et al. Optimizing chimeric Antigen receptor T-Cell therapy for adults with Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(5):415–22.
Article
CAS
Google Scholar
Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543–51.
Article
CAS
Google Scholar
Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, et al. Long-term outcomes from a randomized dose optimization study of chimeric Antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2862–71.
Article
CAS
Google Scholar
Geyer MB, Riviere I, Senechal B, Wang X, Wang Y, Purdon TJ, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 2019;5.
Sauter CS, Senechal B, Riviere I, Ni A, Bernal Y, Wang X, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-hodgkin lymphoma. Blood. 2019;134(7):626–35.
Article
CAS
Google Scholar
Roddie C, Dias J, O’Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric Antigen Receptor-T therapy in adults with relapsed or refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2021;39(30):3352–63.
Article
CAS
Google Scholar
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
Article
Google Scholar
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210–21.
Article
Google Scholar
Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.
Article
CAS
Google Scholar
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
Article
CAS
Google Scholar
Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric Antigen receptors for relapsed or refractory Hodgkin Lymphoma: an open-label phase I Trial. Clin Cancer Res. 2017;23(5):1156–66.
Article
CAS
Google Scholar
Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, et al. Potent anti-leukemia activities of chimeric Antigen receptor-modified T cells against CD19 in chinese patients with Relapsed/Refractory Acute lymphocytic leukemia. Clin Cancer Res. 2017;23(13):3297–306.
Article
CAS
Google Scholar
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
Article
Google Scholar
Meader N, King K, Llewellyn A, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. 2014;3:82. https://doi.org/10.1186/2046-4053-3-82 [published Online First: 20140724].
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64(12):1283–93. https://doi.org/10.1016/j.jclinepi.2011.01.012 [published Online First: 20110811].
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol. 2011;64(12):1303–10. https://doi.org/10.1016/j.jclinepi.2011.04.014 [published Online First: 20110730].
Li M, Xue SL, Tang X, Xu J, Chen S, Han Y, et al. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Sci Rep. 2022;12(1):378.
Article
CAS
Google Scholar
Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4.
Article
Google Scholar
Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, et al. Characteristics and risk factors of Cytokine Release Syndrome in chimeric Antigen receptor T cell treatment. Front Immunol. 2021;12:611366.
Article
CAS
Google Scholar
Yanez L, Sanchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3(2):e186.
Article
Google Scholar
Yu WL, Hua ZC. Chimeric Antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: efficacy and Safety-A systematic review with Meta-analysis. Cancers (Basel). 2019;11(1).
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, et al. Risks and benefits of chimeric Antigen receptor T-Cell (CAR-T) therapy in Cancer: a systematic review and Meta-analysis. Transfus Med Rev. 2019;33(2):98–110.
Article
Google Scholar
Pettitt D, Arshad Z, Smith J, Stanic T, Hollander G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical Trial Landscape. Mol Ther. 2018;26(2):342–53.
Article
CAS
Google Scholar
Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, et al. Chimeric antigen receptor T-cells safety: a pharmacovigilance and meta-analysis study. Am J Hematol. 2021;96(9):1101–11.
Article
CAS
Google Scholar
Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, et al. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021;13(15).
Wu X, Zhang X, Xun R, Liu M, Sun Z, Huang J. Efficacy and safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma patients with secondary CNS involvement: a systematic review. Front Immunol. 2021;12:693200.
Article
CAS
Google Scholar
Anwer F, Shaukat AA, Zahid U, Husnain M, McBride A, Persky D, et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy. 2017;9(2):123–30.
Article
CAS
Google Scholar
Sun Z, Xun R, Liu M, Wu X, Qu H. The Association between Glucocorticoid Administration and the risk of impaired efficacy of Axicabtagene Ciloleucel treatment: a systematic review. Front Immunol. 2021;12:646450.
Article
CAS
Google Scholar
Cai C, Tang D, Han Y, Shen E, Ahmed OA, Guo C, et al. A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging. 2020;12(18):18741–53.
Article
CAS
Google Scholar
Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CARTcell therapy. CRS NT and financial burden2019:[12 p.]. Available from: https://ascopubs.org/doi/full/10.1200/EDBK_238691.
Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious complications following CD19 chimeric Antigen receptor T-cell therapy for children, adolescents, and young adults. Open Forum Infect Dis. 2020;7(5):ofaa121.
Article
Google Scholar
Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140(4):349–58.
CAS
Google Scholar
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–30.
Article
CAS
Google Scholar
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.
Article
CAS
Google Scholar
Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295–306.
Article
CAS
Google Scholar
Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016;127(26):3312–20.
Article
CAS
Google Scholar
Barros LRC, Paixao EA, Valli AMP, Naozuka GT, Fassoni AC, Almeida RC. CARTmath-A Mathematical Model of CAR-T immunotherapy in preclinical studies of hematological cancers. Cancers (Basel). 2021;13(12).
Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK, et al. Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2022. https://doi.org/10.1182/bloodadvances.2022007246.
Dasyam N, George P, Weinkove R. Chimeric antigen receptor T-cell therapies: optimising the dose. Br J Clin Pharmacol. 2020;86(9):1678–89.
Article
CAS
Google Scholar